RxDoctor Payments Data

Georges Ghafari, MD

Cardiovascular Disease · St Clair Shores, MINPI 1699725606

Payments from drug & device makers

$1,263in general payments, 2019–2025

Across 18 payments — averaging $70.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$342
  • Abbott$241
  • Impulse Dynamics (USA) Inc.$174
  • Atricure, Inc.$134
  • Bayer$118
  • Pfizer$77
  • plus $177 from 5 others

What the payments were for

  • Food & beverage$1,24098%
  • Education$232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,263 in reported general payments places this provider in the 35th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$231,979
Medicare patients
784
Services billed
2,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban492$546,813
XareltoRivaroxaban165$179,744
EntrestoSacubitril/Valsartan33$45,275
Repatha SureclickEvolocumab27$19,005
Metoprolol Succinate495$9,084
Rosuvastatin Calcium352$8,225
Atorvastatin Calcium486$7,010
Carvedilol251$3,856
Losartan Potassium213$3,776
Ranolazine ErRanolazine17$3,266
Lisinopril324$2,868
Metoprolol Tartrate300$2,812
Diltiazem 24hr Er (Cd)Diltiazem Hcl54$2,428
Amlodipine Besylate327$2,283
SotalolSotalol Hcl71$2,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$77$546,813492 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in St Clair Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →